Head-to-head evidence
BCD-248 vs GR1803
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: BCMA x CD3 · full Multiple Myeloma pipeline
BCD-248
Developed by Biocad
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: July 2028 · NCT07742215 (registry estimate)
GR1803
Developed by Genrix Bio
NCT07102706 · Phase 1/2 · completed
The study assigned participants sequentially to different GR1803 doses without randomization, blinding, or a control group. Its primary endpoint was dose-limiting toxicity over 52 weeks, but the registry does not report whether this endpoint was met.
Next expected readout: May 2027 · NCT06566547 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BCD-248's landscape · GR1803's landscape